Shofiyah Hasya, . (2022) EFIKASI ANTI IL-6 RECEPTOR MONOCLONAL ANTIBODY SEBAGAI TERAPI ADJUVAN PASIEN COVID-19 DENGAN CYTOKINE RELEASE SYNDROME: Sebuah Tinjauan Sistematis. Skripsi thesis, Universitas Pembangunan Nasional Veteran Jakarta.
![[img]](http://repository.upnvj.ac.id/style/images/fileicons/text.png) |
Text
ABSTRAK.pdf Download (51kB) |
|
Text
AWAL.pdf Download (1MB) |
|
Text
BAB 1.pdf Download (112kB) |
|
Text
BAB 2.pdf Restricted to Repository UPNVJ Only Download (965kB) |
|
Text
BAB 3.pdf Restricted to Repository UPNVJ Only Download (240kB) |
|
Text
BAB 4.pdf Restricted to Repository UPNVJ Only Download (299kB) |
|
Text
BAB 5.pdf Download (77kB) |
|
Text
DAFTAR PUSTAKA.pdf Download (113kB) |
|
Text
RIWAYAT HIDUP.pdf Restricted to Repository UPNVJ Only Download (88kB) |
|
Text
LAMPIRAN.pdf Restricted to Repository UPNVJ Only Download (415kB) |
|
Text
HASIL PLAGIARISME.pdf Restricted to Repository staff only Download (180kB) |
|
Text
ARTIKEL KI.pdf Restricted to Repository staff only Download (345kB) |
Abstract
Introduction: Cytokine release syndrome (CRS) take an important role in the progression of acute respiratory distress syndrome or multi-organ damage in severe COVID-19 patients. Several studies stated interleukin 6 including the main cytokine in the occurrence of CRS. We are interested in assessing anti-IL-6 receptor monoclonal antibodies, such as tocilizumab and sarilumab, which have potential as immunomodulators in adjuvant therapy for COVID-19 patients. Methods: We reviewed relevant Randomized Controlled Trial (RCT) studies from PubMed, Google Scholar, and EBSCO MEDLINE up to December 2021. The primary outcome included the requirement for invasive mechanical ventilation/other organ life-support, with the secondary outcome was incidence of adverse events. The risk of bias of each study was assessed using the Cochrane Risk-of-Bias Tool for Randomized Trials (RoB 2). Results: Sixteen RCT studies met the eligibility criteria involving 6,762 patients. There was an association between anti IL-6 receptor monoclonal antibodies and the requirement for IVM/other organ life support (602/3641 [16.5%] in the intervention group vs 777/3394 [23%] in the control group, RR = 0.77; 95% CI [0.72, 1.21]; P < 0.00001; I2 = 20%). There were no serious adverse events associated with the treatment. Conclusion: Anti-IL-6 receptor monoclonal antibodies are potentially safe and reduce the requirement for intubation when given concomitantly with steroids in COVID-19 patients with CRS. However, further recommendations of anti-IL-6 receptor monoclonal antibodies for COVID-19 patients, particularly sarilumab, should continue to be corroborated by high-quality evidence from randomized controlled trials. Keywords: COVID-19, Cytokine Release Syndrome, Monoclonal Antibody, Interleukin 6 (IL-6)
| Item Type: | Thesis (Skripsi) |
|---|---|
| Additional Information: | No. Panggil: 1810211049 Pembimbing 1: Yanto Sandy Tjang Pembimbing 2: Riezky Valentina Astari Penguji: Yudhi Nugraha |
| Uncontrolled Keywords: | COVID-19, Cytokine Release Syndrome, Monoclonal Antibody, Interleukin 6 (IL-6) |
| Subjects: | R Medicine > R Medicine (General) R Medicine > RM Therapeutics. Pharmacology |
| Divisions: | Fakultas Kedokteran > Program Studi Kedokteran (S1) |
| Depositing User: | Shofiyah Hasya |
| Date Deposited: | 22 Feb 2022 02:03 |
| Last Modified: | 22 Feb 2022 02:03 |
| URI: | http://repository.upnvj.ac.id/id/eprint/16291 |
Actions (login required)
 |
View Item |